The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal ulcer", "anastomotic ulcer", "reflux oesophagitis", "non-erosive reflux disease", or "Zollinger-Ellison syndrome"
Nexium capsules Clinical Experience Investigation
Study Type
OBSERVATIONAL
Enrollment
3,691
Number of Adverse Drug Reactions
Time frame: Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks
Number of Adverse Drug Reactions
Time frame: Patients with duodenal ulcer: 6 weeks
Number of Adverse Drug Reactions
Time frame: Patients with reflux oesophagitis: 8 weeks
Number of Adverse Drug Reactions
Time frame: Patients with non-erosive reflux disease: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Aichi, Japan
Research Site
Akita, Japan
Research Site
Aomori, Japan
Research Site
Chiba, Japan
Research Site
Ehime, Japan
Research Site
Fukui, Japan
Research Site
Fukuoka, Japan
Research Site
Fukushima, Japan
Research Site
Gifu, Japan
Research Site
Gunma, Japan
...and 37 more locations